Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Inclusion Criteria: * Adult patients ≥ 18 years of age with one or more brain tumors planned for neurosurgical resection/biopsy * Pathologically-documented glioblastoma; or * Metastatic cancer that: o Has a history of Her2 expression or activating Her2-mutation * Her2+ defined as 3+ on IHC * Her2-low defined as IHC1+ or 2+ and ISH- according to ASCO-CAP 2018 Her2 testing guidelines52 * Her2 mutations must be described to be activating, occur at a known hotspot (e.g. exon 20 insertions, S310, G660, R678, L755, D769, L777), or involve the transmembrane, juxtamembrane or tyrosine kinase domai…
All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
Arctuva estimate
Verify or correct the compensation shown for this listing.